Bi
Non vérifié

Biomunex Pharmaceuticals

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueOncologieSanté
14/09/2026
Oncologie
Santé
Hygiène alimentaire
Santé Publique
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Industrie
Biomunex Announces the Upcoming Start of Clinical Development of IPN60330, the First MAIT Engager, a New Therapeutic Class in Oncology, Following the Completion of the FDA Review Period
1.00
26/05/2026
Marché du travail
Industrie
Technique
Science
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Oncologie
Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies
1.00
08/01/2026
Oncologie
Santé
Science
Industrie pharmaceutique
Biotechnologie
Événements
Industrie
Biomunex Pharmaceuticals will showcase its MAIT Engager Platform during the 11th Annual Oncology Innovation Forum in San Francisco
1.00
07/11/2025
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Médecine - Divers
Expos
Événements
Industrie
Biomunex to Present Preclinical Data of its MAIT Engager Platform in Immuno-Oncology at 2025 SITC Annual Meeting
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0